FMR1 and the fragile X syndrome: Human genome epidemiology review

• Published in: Genetics in medicine Vol. 3; no. 5; pp. 359 - 371
• Main Authors: Crawford, Dana C., Acuña, Juan M., Sherman, Stephanie L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2001
• Subjects: epidemiology; Female; FMR1; Fragile X Mental Retardation Protein; fragile X syndrome; Fragile X Syndrome - epidemiology; Fragile X Syndrome - genetics; FRAXA; Gene Frequency - genetics; Genetic Testing; Genome, Human; Heterozygote; Humans; Male; mental retardation; Mutation - genetics; Nerve Tissue Proteins - genetics; review; RNA-Binding Proteins; Trinucleotide Repeats - genetics; Whites - genetics; mental retardation; epidemiology; FMR1; review; FRAXA; fragile X syndrome
• ISSN: 1098-3600; 1530-0366
• DOI: 10.1097/00125817-200109000-00006

The fragile X syndrome, an X-linked dominant disorder with reduced penetrance, is one of the most common forms of inherited mental retardation. The cognitive, behavioral, and physical phenotype varies by sex, with males being more severely affected because of the X-linked inheritance of the mutation. The disorder-causing mutation is the amplification of a CGG repeat in the 5′ untranslated region of FMR1 located at Xq27.3. The fragile X CGG repeat has four forms: common (6–40 repeats), intermediate (41–60 repeats), premutation (61–200 repeats), and full mutation (>200–230 repeats). Population-based studies suggest that the prevalence of the full mutation, the disorder-causing form of the repeat, ranges from 1/3,717 to 1/8,918 Caucasian males in the general population. The full mutation is also found in other racial/ethnic populations; however, few population-based studies exist for these populations. No population-based studies exist for the full mutation in a general female population. In contrast, several large, population-based studies exist for the premutation or carrier form of the disorder, with prevalence estimates ranging from 1/246 to 1/468 Caucasian females in the general population. For Caucasian males, the prevalence of the premutation is ∼1/1,000. Like the full mutation, little information exists for the premutation in other populations. Although no effective cure or treatment exists for the fragile X syndrome, all persons affected with the syndrome are eligible for early intervention services. The relatively high prevalence of the premutation and full mutation genotypes coupled with technological advances in genetic testing make the fragile X syndrome amenable to screening. The timing as well as benefits and harms associated with the different screening strategies are the subject of current research and discussion.